32 results about "Env Glycoproteins" patented technology

A viral particle. The surface of the viral particle comprises a T cell activation primary signaling molecule and a T cell activation secondary signaling molecule; the envelope glycoprotein of the viral particle is subjected to a first mutation, so that the receptor binding ability of the viral glycoprotein is weakened or lost with respect to its receptor binding ability before the first mutation; and the envelope glycoprotein of the viral particle can also be subjected to a second mutation, so that the viral particle has enhanced resistance to complement-mediated inactivation or is not subjected to complement-mediated inactivation. The viral particle has improved specificity for targeted activation, stimulation and transduction of non-activated T cells, and is thus more applicable for the preparation of CAR-T cells in subjects.

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The invention provides BaEV-G envelope glycoprotein, an optimization method of the BaEV-G envelope glycoprotein and an envelope plasmid, a packaging method and a kit which relate to the BaEV-G envelope glycoprotein, and particularly relates to the optimization method of the BaEV-G envelope glycoprotein, chimeric BaEV-G envelope glycoprotein, a lentivirus envelope plasmid, a pseudotyped packaging method of lentivirus and the kit. The BaEV-G envelope glycoprotein and the VSV-G envelope glycoprotein are chimeric to obtain the chimeric BaEV-G envelope glycoprotein, and the properties of lentivirus packaging efficiency, biological activity and the like can be effectively improved.

The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The application provides a BaEV-G envelope glycoprotein, an optimization method thereof, and an envelope plasmid, a packaging method and a kit related to the envelope glyprotein, in particular, relates to an optimization method of a BaEV-G envelope glyprotein, a chimeric BaEV-G envelope glyprotein, a lentivirus envelope plasmid, a lentivirus pseudotyped packaging method and a kit. The BaEV-G envelope glyprotein is chimerized with the VSV-G envelope glyprotein to obtain the chimeric BaEV-G envelope glyprotein, so that the lentivirus packaging efficiency, biological activity and other performances can be effectively improved.

This invention relates to the field of vaccine preparation technology, specifically disclosing a VSV-based HTNV vaccine, its preparation method, and its application. The method involves constructing a recombinant plasmid by inserting the nucleotide sequence of the HTNV envelope glycoprotein into the recombinant VSV vector plasmid, followed by packaging and processing to obtain an immunogenic HTNV recombinant VSV vaccine. The HTNV vaccine prepared by this invention provides a novel candidate vaccine for the prevention and treatment of hemorrhagic fever with renal syndrome.

The invention provides a mutant VSVG and a targeting carrier, and belongs to the field of carrier delivery. There is provided an envelope glycoprotein of a vesicular stomatitis virus having a first mutation and a second mutation, the first mutation causing the envelope glycoprotein not to mediate complement inactivation; the second mutation weakens the ability of the envelope glycoprotein to be recognized by a receptor. The invention also provides a targeting vector which comprises a first molecule combined with an endocytosis receptor of a target cell and a second molecule which is non-complement-inactivated and is used for promoting a substance carried by the targeting vector to release and enter cytoplasm, and the second molecule promotes endosome escape or lysosome escape of the targeting carrier, and prevents the targeting carrier from being inactivated by the complement.

Provided herein are compositions, systems, kits and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) with a composition i) comprising a plurality of nanoparticles self-assembled by a plurality of fusion proteins comprising a) at least a portion of a ferritin and b) an immunogenic protein, in some embodiments, the fusion protein comprises i) an immunogenic protein comprising at least a portion of an SFTS virus Gn and / or Gc envelope glycoprotein, or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The invention belongs to the technical field of medical biology, and particularly relates to an EBV (Epstein-Barr Virus) neutralizing antibody-specifically-immune plasma high-throughput screening method and application thereof. EB virus envelope glycoprotein gp350 is selected as a screening target antigen, EBV specific plasma containing a high-titer EBV neutralizing antibody is rapidly screened in a high-throughput mode and used for preparing EBV specific human immune globulin, the titer of the EBV neutralizing antibody is obviously higher than that of listed intravenous gamma-C products, and the content of the EBV neutralizing antibody is about 4-8 times that of the EBV neutralizing antibody with the same concentration. The method provided by the invention can realize large-scale collection of EBV specific plasma through rapid high-throughput screening, reduces the workload of plasma screening, is suitable for large-scale production of EBV specific human immune globulin, and has a good application prospect.

The present invention provides a mutant vesicular stomatitis virus G glycoprotein (VSVG) and a targeting vector, relating to the area of ​​vector delivery. The present invention provides an envelope glycoprotein of vesicular stomatitis virus having a first mutation and a second mutation, wherein the first mutation prevents the envelope glycoprotein from mediating complement-mediated inactivation, and the second mutation reduces the envelope glycoprotein's ability to be recognized by a receptor. The present invention further provides a targeting vector comprising a first molecule that binds to an endocytosis receptor of a target cell, and a second molecule that promotes the release of a substance carried on the targeting vector into the cytoplasm rather than causing complement inactivation, wherein the second molecule promotes the occurrence of endosomal or lysosomal escape by the targeting vector and prevents the targeting vector from being inactivated by complement.

To provide methods for selectively modulating the activity of distinct subtypes of cells.SOLUTION: The invention relates to a pseudotyped retrovirus-like particle or retroviral vector comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family, one fused to a cell-targeting domain and the other fused to a functional domain. The invention also relates to the use of the pseudotyped retrovirus-like particle or retroviral vector that selectively modulates a specific subset of cells, in particular activities of specific immune cells. The pseudotyped retrovirus-like particle or retroviral vector is particularly useful for gene therapy, immunotherapy and / or vaccination.SELECTED DRAWING: None

The invention belongs to the technical field of microbial immunity and DNA vaccines, and particularly relates to a preferred epitope peptide of a Crimean-Congo hemorrhagic fever virus envelope glycoprotein C terminal (CCHFV Gc), a tandem multi-epitope vaccine, an expression vector and application. The preferable epitope peptide is composed of any one amino acid sequence as shown in SEQ ID NO.1-SEQ ID NO.21, and the preferable epitope peptide has high affinity, strong immunogenicity and interspecific amp; and an intraspecific conservative preferred epitope. Preferably epitopes are connected in series through a linker to synthesize a series multi-epitope vaccine, the series multi-epitope vaccine enters cells to be expressed to form recombinant protein, then T lymphocytes are activated, and cellular immune response is induced. The in-vivo vaccine evaluation of animals is carried out by using the tandem multi-epitope vaccine, and it is proved that the vaccine can effectively induce anti-CCHFV specific cellular immune response and the application safety in BALB / c mice. The invention is helpful for understanding the immunobiology of CCHFV Gc and perfecting the epitope vaccine design for the virus in the future.

The HIV-1 envelope glycoprotein (Env) is the sole neutralizing determinant on the viral surface. The Env gpl20 and gp41 subunits mediate receptor binding and membrane fusion. HIV- 1 neutralizing antibodies can be generated following immunization via expressing membrane-bound Env anchored on the cell-surface genetically using the natural HIV gp41 transmembrane (TM) spanning domain. Inventors used "native flexibly linked" (NFL) stabilized soluble trimers that are both near-native in conformation and cleavage-independent. The NFL construct was genetically fused to the HIV TM domain using a short linker or restoring the native membrane external proximal region to express the full HIV Env ectodomain on the plasma membrane. Both forms of cell-surface NFL trimers, without and with the MPER, displayed favorable antigenic profiles when expressed from plasmid DNA or mRNA. Inoculation of rabbits with mRNA lipid nanoparticles (LNP) expressing membrane-bound stabilized HIV Env NFL trimers generated tier 2 neutralizing antibody serum titers in immunized animals.

The present disclosure provides compositions and methods for the selective transduction and genome editing of human cells (e.g., hematopoietic stem and progenitors cells, HSPCs) using engineered viral like particles (eVLPs). Aspects of the disclosure provide eVLP compositions comprising fusion proteins comprising a targeting moiety. In some embodiments, the fusion proteins comprise a cytokine conjugated to a transmembrane protein and / or an envelope glycoprotein. In other embodiments, the fusion proteins comprise a targeting moiety domain, a stalk protein domain, a transmembrane and / or envelope glycoprotein domain. Targeted-eVLP architectures comprising various targeting domains, stalk domains, transmembrane domains, and envelope glycoproteins are also provided herein. Other aspects of the disclosure provide eVLP compositions comprising envelope glycoproteins comprising non-natural sugars and methods of conjugating said eVLPs to various targeting moieties using bio-orthogonal click chemistry. Polynucleotides, vectors, cells, and kits useful for producing the articles, and performing the methods, described herein are also provided.

The present invention reveals MESD as a critical host dependency factor for Oropouche virus (OROV) infection. Initial identification was achieved through a CRISPR-Cas9 loss-of-function screen, which highlighted MESD amongst other potential factors. The ensuing research demonstrated that MESD knockout in HEK293T cells resulted in a significant reduction in OROV infection rates. Complementing MESDKO cells with FLAG-MESD re-established susceptibility, thus confirming MESD's essential role in the infection process. Interestingly, MESD specifically facilitates OROV infection without enhancing the infectivity of other viruses such as LACV, TOSCV, and WNV. The specificity of MESD for OROV was further validated by its interaction with OROV envelope glycoproteins, as shown through immunoprecipitation assays. These findings suggest that targeting MESD could be a novel and effective approach for diagnosing and treating OROV infections, potentially paving the way for innovative therapeutic strategies against this virus.

The present disclosure provides compositions comprising E2 envelope glycoprotein from HCV Gt3 strain S52. Surprisingly, this composition provides an immune response effective against heterologous HCV strains, e.g., Gt1 strain H77 and Gt2 strain J6. These compositions may be used for inducing an immune response to HCV Gt1-Gt3, e.g., Gt1 strain H77, Gt2 strain J6, and Gt3 strain S52 in an individual.

A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and / or d) is presented on a dimer of Envelope proteins; and / or c) is formed from consecutive or nonconsecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and / or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4. The EDE may be a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and / or covalently stabilized with at least one sulfhydrylreactive crosslinker between the two sE monomers, and / or covalently stabilized by linking the two sE monomers through modified sugars; and / or, covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and / or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1) / domain 3 (D3) linker of each monomer. A compound, for example an antibody or antibody fragment that can neutralize more than one Dengue virus serotype, for example an antibody that can bind to an EDE of the invention.

The application provides an antibody against gp350 and a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 1-3, SEQ ID No. 13-15 or SEQ ID No. 25-27, and the amino acid sequence of the light chain variable region is shown in SEQ ID No. 4-6, SEQ ID No. 16-18 or SEQ ID No. 28-30. The anti-gp350 antibody screened in the application can specifically combine with the EBV virus envelope glycoprotein gp350 antigen, and the affinity is between 10 ‑9 ~ 10 ‑ 7 M orders of magnitude. The antibody of the application can be used to prepare a medicine for preventing and / or treating tumors or autoimmune diseases, and has a wide application prospect.

The invention discloses a vector and application thereof in the field of gene delivery. The vector is a virus-enveloped virus vector, wherein (a) the surface of the virus-enveloped virus vector comprises one or more ligands specifically combined with a lymphocyte endocytosis receptor; (b) the envelope glycoprotein of the virus-enveloped virus vector is subjected to first mutation, so that the ability of the envelope glycoprotein to specifically bind to a receptor is weakened or lost; and (c) the envelope glycoprotein of the virus-enveloped virus vector can be subjected to second mutation, so that the capability of antagonizing complement inactivation of the virus-enveloped virus vector is enhanced or the virus-enveloped virus vector is not inactivated by complement.

This invention provides a method for efficient multi-gene editing and CAR site-directed integration based on BaEV envelope glycoprotein truncated viral particles and its application in immune cell engineering. The invention provides an MLV-VLP system utilizing BaEV envelope glycoprotein truncated particles to achieve efficient CRISPR-Cas9 delivery without electroporation or the use of randomly integrating viruses. Combined with adeno-associated virus (AAV6) delivery of HDR templates, it enables efficient site-directed integration of CAR sequences at target sites (such as TRAC, PD1, and B2M) in primary human T cells and NK cells. The prepared CAR-T or CAR-NK cells exhibit excellent cell killing, proliferation, and low exhaustion characteristics in vitro, achieving 100% tumor clearance in an in vivo mouse model. It can simultaneously achieve multi-gene knockout with high efficiency, supporting large-scale allogeneic CAR-T and CAR-NK cell production.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

An object of the present invention is to provide an effective vaccine that can prevent and treat infection with CMV. A fusion protein of the present invention is a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of the cytomegalovirus (CMV). A vaccine for prevent or treat infection with cytomegalovirus (CMV) of the present invention is a subunit vaccine containing a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of CMV as an antigen.

The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and / or gH and / or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).

The present disclosure belongs to the field of biotechnology, and specifically relates to a method for efficiently infecting human natural killer (NK) cells and other immune cells with a pseudovirus. Specifically, a viral transfection system provided in the present disclosure has an envelope plasmid with a protein having an X-Y-Z structure. The X is an extracellular (ex) structure of a gibbon ape leukemia virus (GALV) envelope glycoprotein, the Y is a transmembrane (TM) structure of the GALV envelope glycoprotein, and the Z is an intracellular segment portion of a murine virus gene.

A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and / or d) is presented on a dimer of Envelope proteins; and / or c) is formed from consecutive or nonconsecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and / or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4. The EDE may be a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, wherein the dimer is: covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers, and / or covalently stabilized with at least one sulfhydryl-reactive crosslinker between the two sE monomers, and / or covalently stabilized by linking the two sE monomers through modified sugars; and / or, covalently stabilised by being formed as a single polypeptide chain, optionally with a linker region, optionally a Glycine Serine rich linker region, separating the sE sequences, and / or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1) / domain 3 (D3) linker of each monomer. A compound, for example an antibody or antibody fragment that can neutralise more than one Dengue virus serotype, for example an antibody that can bind to an EDE of the invention.

The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention.